Does Blue Cross Blue Shield of Arizona Cover Dupixent?

What Is Dupixent and Why Does Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks both IL-4 receptor alpha signaling and IL-13 signaling, two cytokines central to type 2 inflammatory disease. The FDA approved dupilumab for moderate-to-severe atopic dermatitis in adults in March 2017, and the label has since expanded to cover six distinct conditions across multiple age groups. The full prescribing information is maintained on the FDA's accessdata portal.

Why the Price Makes Coverage Critical

Without insurance, Dupixent costs roughly $3,800 per 28-day supply. For most patients, that equals more than $45,000 per year. Even with insurance, specialty-tier cost-sharing can reach 20 to 30% of that figure. A 2021 analysis published in JAMA Dermatology found that out-of-pocket costs for biologic dermatology drugs remained the single largest barrier to treatment initiation and adherence among commercially insured patients. Read the analysis on PubMed.

FDA-Approved Indications Relevant to Coverage Decisions

BCBSAZ will only cover Dupixent for uses that appear on the FDA label or in recognized clinical compendia. The current approved indications include:

• Moderate-to-severe atopic dermatitis in patients age 6 months and older whose disease is not adequately controlled with topical therapies
• Moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma (age 6 and older)
• Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults
• Eosinophilic esophagitis (EoE) in patients age 12 and older weighing at least 40 kg
• Prurigo nodularis in adults age 12 and older
• Inadequately controlled COPD with an eosinophilic phenotype in adults

Each indication carries its own prior authorization criteria, and BCBSAZ reviews them separately.

Does BCBSAZ Actually Cover Dupixent?

Yes. BCBSAZ covers Dupixent on its specialty formulary across commercial, ACA marketplace, and most employer-sponsored plans, but coverage is never automatic. Every plan tier requires prior authorization before the first fill is dispensed.

Formulary Tier Placement

On most BCBSAZ commercial formularies, Dupixent sits on Tier 4 or Tier 5 (specialty). That placement matters because specialty tiers carry the highest cost-sharing percentages, often 20 to 30% coinsurance after the deductible. The specific tier varies by the individual plan document (called the Summary of Benefits and Coverage, or SBC), so patients should log into their BCBSAZ member portal or call the member services number on their insurance card to confirm tier placement for their specific plan year.

Medical vs. Pharmacy Benefit

BCBSAZ may process Dupixent claims through either the pharmacy benefit or the medical benefit depending on the plan:

• Pharmacy benefit: Dupixent is dispensed through a specialty pharmacy (most commonly Accredo or CVS Specialty) and processed like a prescription drug.
• Medical benefit: When a physician administers Dupixent in-office, the claim may go through the medical benefit under the physician's billing codes (J-code J0173 for dupilumab).

Patients receiving at-home self-injection typically use the pharmacy benefit. Knowing which benefit applies is critical because cost-sharing structures differ.

How Prior Authorization Works for Dupixent at BCBSAZ

Prior authorization (PA) is a formal review process that requires the prescribing physician to submit clinical evidence showing that Dupixent is medically necessary for a specific patient. BCBSAZ follows criteria derived from evidence-based guidelines, including those published by the American Academy of Dermatology (AAD) for atopic dermatitis. The AAD's 2023 atopic dermatitis guidelines are available at the AAD's journal via PubMed.

Typical PA Criteria for Atopic Dermatitis

For the most common indication (moderate-to-severe atopic dermatitis), BCBSAZ typically requires:

1. A confirmed diagnosis by a board-certified dermatologist or allergist
2. Disease severity documentation (EASI score, IGA score, or BSA involvement)
3. Documented trial and inadequate response to at least one medium-to-high-potency topical corticosteroid for a minimum of 4 to 8 weeks
4. Documentation that topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) were tried or are contraindicated
5. Confirmation that the patient is not pregnant or that the benefit-risk has been discussed

Some plans also require a trial of dupilumab-naïve systemic immunosuppressants (cyclosporine, methotrexate) before approving the biologic, though this is less common for atopic dermatitis given the FDA label language. The key SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks produced IGA 0/1 ("clear" or "almost clear") in 37% of patients versus 10% of placebo patients at 16 weeks, supporting the label's positioning as a post-topical-failure therapy. Read the SOLO 1 and SOLO 2 results on NEJM.

Typical PA Criteria for Asthma

For the asthma indication, BCBSAZ typically requires:

1. Confirmed moderate-to-severe persistent asthma diagnosis
2. Blood eosinophil count of at least 150 cells/microliter (some plans require 300 cells/microliter)
3. Documented uncontrolled asthma on medium-to-high-dose inhaled corticosteroid plus long-acting beta-agonist therapy
4. Spirometry confirming airflow obstruction

The LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab reduced severe exacerbation rates by 47.7% in patients with baseline eosinophils at or above 300 cells/microliter, compared with placebo. See the QUEST trial on PubMed.

PA for Other Indications

CRSwNP, EoE, and prurigo nodularis each carry analogous step-therapy requirements. For EoE, BCBSAZ typically requires documented failure of proton pump inhibitor therapy and at least one dietary elimination trial or topical swallowed corticosteroid trial before approving dupilumab. The LIBERTY-EoE TREET trial (N=321) showed dupilumab 300 mg every two weeks achieved histologic remission (less than 6 eosinophils per high-power field) in 59% of patients at week 24. Read the TREET trial results on PubMed.

Timeline for PA Decisions

Under Arizona state insurance law and federal ACA regulations, non-urgent PA decisions must be issued within 3 business days of receiving a complete request. Urgent (expedited) PA decisions must be issued within 72 hours. If BCBSAZ requests additional information, the clock pauses until the prescriber responds.

What Happens If BCBSAZ Denies Coverage?

Denial is not the end of the road. Federal law under the ACA and Arizona state regulations guarantee patients the right to both internal and external appeals.

Internal Appeal

An internal appeal asks BCBSAZ's own medical reviewers to re-examine the denial. The appeal must be filed within 180 days of the denial notice. The prescriber should submit:

• A detailed letter of medical necessity explaining why step-therapy alternatives are insufficient or have failed
• Peer-reviewed literature supporting dupilumab for the specific indication
• Any relevant objective severity scores (EASI, DLQI, SNOT-22, peak expiratory flow logs)

Research from the Kaiser Family Foundation found that approximately 40 to 60% of internally appealed denials for specialty biologics are overturned at this stage, particularly when the prescriber submits adequate clinical documentation.

External Independent Review

If the internal appeal fails, Arizona law allows patients to request an external independent medical review organization (IRO) to evaluate the denial. The IRO's decision is binding on BCBSAZ. Patients can also file a complaint with the Arizona Department of Insurance and Financial Institutions (DIFI).

Peer-to-Peer Review

Before filing a formal appeal, the prescribing physician should request a peer-to-peer (P2P) phone call with the BCBSAZ medical director overseeing the denial. This conversation often resolves denials faster than a written appeal. The prescriber should call as soon as the denial arrives, because PA decisions that are overturned at P2P review are generally processed within 24 to 48 hours.

How Much Will Dupixent Cost With BCBSAZ Coverage?

Even with an approved prior authorization, cost-sharing remains significant for many patients on specialty-tier formularies.

Estimating Your Out-of-Pocket Cost

The formula is straightforward:

• If your plan uses coinsurance (e.g., 30%), you pay 30% of the contracted rate (not the list price) after your deductible is met.
• If your plan uses a copay (e.g., $150 per fill), you pay that fixed amount.
• Before meeting your deductible, you may pay the full contracted rate for each fill.

Annual out-of-pocket maximums cap total cost-sharing for in-network services. For 2024, ACA marketplace plans cap out-of-pocket costs at $9,450 for individuals and $18,900 for families. Once that cap is reached, BCBSAZ pays 100% for covered services.

Sanofi's Dupixent MyWay Copay Card

Sanofi offers the Dupixent MyWay program, which can reduce the monthly cost of Dupixent to $0 for commercially insured patients who meet eligibility criteria. Key eligibility rules:

• The patient must have commercial (private) insurance that covers Dupixent
• The patient must not be covered by any federal or state government insurance program (Medicare, Medicaid, CHIP, TRICARE)
• Income thresholds may apply for some program tiers

Patients can enroll through Sanofi's program portal or by calling 1-844-DUPIXENT. The copay card value can reach up to $13,000 per year.

Medicare and Medicaid Patients

The Sanofi copay card is not available for Medicare or Medicaid beneficiaries. Medicare Part D beneficiaries can access Dupixent through Part D specialty drug coverage, but cost-sharing in the catastrophic phase was historically high. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D enrollees, effective January 2025, will reduce this burden substantially. The CMS summary of the Inflation Reduction Act Part D changes is available on the CMS website.

For Medicaid patients in Arizona, coverage is managed through Arizona's AHCCCS program. AHCCCS covers Dupixent for Medicaid-eligible patients but applies its own prior authorization criteria, which may differ from commercial plan criteria.

Sanofi Patient Assistance Program for Uninsured or Denied Patients

Patients who are uninsured, underinsured, or have been denied coverage may qualify for the Dupixent Patient Assistance Program (PAP), which provides Dupixent at no cost. Eligibility is income-based. Patients can apply through the Dupixent MyWay program or through NeedyMeds. NeedyMeds maintains a current database of patient assistance programs at needymeds.org, and the FDA's database of patient assistance resources is available via FDA.gov.

What Clinicians Say About Dupixent's Clinical Necessity

The American Academy of Dermatology's 2023 guidelines state: "Dupilumab is recommended for patients with moderate-to-severe atopic dermatitis who have an inadequate response to topical therapies or for whom topical therapies are not advisable." This language directly mirrors the standard prior authorization criteria used by most commercial insurers, including BCBSAZ. See the full AAD guideline on PubMed.

The Global Initiative for Asthma (GINA) 2023 report similarly designates dupilumab as a preferred add-on biologic for type 2 asthma in patients uncontrolled on step 4 to 5 therapy, reinforcing the clinical justification for insurance coverage at that disease stage. The GINA 2023 report is available through the GINA website, which archives evidence on PubMed-indexed sources.

Step-by-Step Action Plan for BCBSAZ Members Seeking Dupixent Coverage

Follow this sequence to maximize the chance of a first-time approval:

Step 1: Confirm Your Benefit and Tier

Log into your BCBSAZ member account at bcbsaz.com, pull up your formulary, and search for "dupilumab" or "Dupixent." Note the tier, the PA requirement status, and any step-therapy requirements listed in the formulary notes.

Step 2: Have Your Prescriber Submit a Complete PA

Incomplete PA requests are the single most common reason for delays. Ask your dermatologist, allergist, or pulmonologist to include all required clinical documentation in the initial submission. Most BCBSAZ PA submissions go through CoverMyMeds or the BCBSAZ provider portal.

Step 3: Enroll in Dupixent MyWay Before the First Fill

Register at dupixent.com/dupixent-myway or call 1-844-DUPIXENT. Even if you are uncertain about your cost-sharing, enrolling early means the copay card is active when your pharmacy processes the first claim.

Step 4: If Denied, Request a Peer-to-Peer Immediately

Call BCBSAZ's provider services line and ask the prescriber to schedule a P2P review. Do this within 48 hours of receiving the denial notice.

Step 5: File a Formal Appeal With Supporting Literature

If P2P fails, file the internal appeal with a letter of medical necessity citing the SOLO 1/SOLO 2 data, the AAD guidelines, and any patient-specific severity documentation. Attach objective severity scores.

Step 6: Request External Review If Needed

Arizona law guarantees the right to an external IRO review. This step is free for the patient and binds BCBSAZ to the outcome.

Special Situations: Age, Pregnancy, and Pediatric Coverage

Pediatric Patients

Dupixent carries FDA approval for atopic dermatitis starting at age 6 months, with weight-based dosing. BCBSAZ covers pediatric indications but may require pediatric-specific PA documentation, including weight-based dosing confirmation and pediatric dermatologist involvement. The LIBERTY AD PRESCHOOL trial (N=162) confirmed dupilumab's efficacy and safety profile in children aged 6 months to 5 years. Read the PRESCHOOL trial on PubMed.

Pregnancy

Dupixent is classified as Pregnancy Category B (animal studies show no fetal risk). The prescribing information notes that limited human pregnancy data exist. BCBSAZ does not categorically exclude pregnant patients from coverage, but prior authorization requests for pregnant patients typically require additional documentation. The full prescribing information including pregnancy data is on the FDA's accessdata portal.

Continuity of Coverage During Plan Changes

Patients who switch BCBSAZ plans mid-year (e.g., during open enrollment or due to a qualifying life event) should confirm that the new plan's formulary covers Dupixent before the switch takes effect. A new PA is typically required for each new plan year or when switching between plan products.

Key Numbers to Keep Accessible

• BCBSAZ Member Services: 1-800-232-2345 (commercial) or the number on your insurance card
• Dupixent MyWay Program: 1-844-DUPIXENT (1-844-387-4936)
• Arizona DIFI (for insurance complaints): 1-800-325-2548
• CoverMyMeds (PA platform commonly used by BCBSAZ providers): covermymeds.com